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Abstract 
Metabolic syndrome (MetS) is known to be associated with elevated serum ferritin levels. 
The possible association with other iron markers has been less well studied. We aimed to 
investigate the cross-sectional association of soluble transferrin receptor (sTfR) and ferritin 
levels with MetS components, insulin resistance and HbA1C. The sample consisted of 725 
adults, aged 19-93 years (284 men, 151 premenopausal and 290 postmenopausal women), 
from the Croatian island of Vis. Serum sTfR and ferritin levels were measured by  
immunoturbidometry and electrochemiluminescence assays, respectively. MetS was defined 
using modified international consensus criteria. Logistic and linear regression analyses were 
conducted to investigate the associations adjusting for age, fibrinogen, smoking, alcohol 
consumption and body mass index. Prevalence of MetS was 48.7%. Standardized values of 
ferritin were positively associated with all of the MetS components (except high blood 
pressure and waist circumference) in men(P<0.05).  Ferritin was significantly associated with 
MetS in men(adjusted odds ratio 95% confidence interval:1.78[1.31-2.42]) and 
postmenopausal women(1.71[1.12-2.62]). Interestingly, sTfR was independently and 
positively associated with insulin resistance (HOMA-IR) in men(adjusted βeta=0.44[0.14 to 
0.75],P=0.004) and postmenopausal women(adjusted βeta coefficient 95% confidence 
interval= 0.34[0.05 to 0.63],P=0.020). However, there was no significant relationship 
between serum sTfR levels and MetS or its components.  Neither ferritin nor sTfR were 
significantly associated with HbA1C (P>0.05). sTfR levels could be spuriously elevated in 
subjects with insulin resistance and without association with MetS or its components. We 
conclude that different markers of iron metabolism are not consistently associated with 
cardiometabolic risk. 
 
 
 
 
Introduction 
 
Associations between high levels of ferritin, the major iron storage protein  that is also an 
acute phase protein, and type 2 diabetes have been described in cross-sectional and 
prospective studies (1, 2). Both iron deficiency and iron overload have been associated with 
cardiovascular disease (3). An association between body iron stores and metabolic syndrome 
(MetS), a cluster of vascular, metabolic and anthropometric abnormalities has also been 
identified (4).  Deleterious effects on insulin signaling as a consequence of pro-oxidant 
effects has been suggested as a potential underlying mechanism (5). However, the nature of 
the relationship between iron status and cardio-metabolic status remains unclear and 
exploration of additional aspects of iron metabolism has been recommended (6).  
 
There are other important proteins in iron metabolism in addition to ferritin, such as 
transferrin and transferrin receptors (7,8).Transferrin receptors are of particular interest since 
they act as a sensor for body iron demands. Iron transport in the plasma is carried out by 
transferrin, which donates iron to cells through its interaction with a specific membrane 
receptor, the transferrin receptor (TfR). A soluble form of the TfR has been identified in 
human serum. Soluble TfR is a truncated monomer of the tissue receptor, lacking its first 100 
amino acids, which circulates in the form of a complex of transferrin and its receptor. The 
higher the body iron stores, the lower the transferrin receptors in cell membranes which in 
turn down-regulates of intestinal iron absorption (9). Increased numbers of transferrin 
receptors in cell membranes reflect body iron deprivation and intestinal iron absorption is up-
regulated as compensatory mechanism. Levels of serum transferrin receptor (sTfR) are 
proportional to tissue concentrations (10). sTfR and ferritin  are influenced by the acute phase 
 
 
response of inflammation and therefore their evaluation should include additional 
measurements of inflammatory markers  (11).   
 
Type 2 diabetes and cardiovascular disease are multi-factorial disorders and the exploration 
of potential new risk factors, such as iron metabolism, is necessary in order to obtain 
information about modification of cardiometabolic risk and a better understanding of 
underlying mechanisms in aetiology. The association between sTfR and cardio-metabolic risk 
factors has not been widely investigated. A recent meta-analysis reported conflicting results 
for the association between sTfR and type 2 diabetes in eight studies and described the 
limited power of the included studies due to small sample sizes (1).Only one study has 
described the association between sTfR and MetS (12) but did not adjust for BMI, and two 
studies have described the association between sTfR and some MetS components 
(13,14).Most of these studies reported no evidence of an association with MetS and very few 
associations with MetS components. Our  primary aim was to investigate whether sTfR levels 
were associated with MetS, its components, insulin resistance and HbA1C in a relatively 
large well-characterised population. We also describe the association between ferritin with 
MetS, its components, insulin resistance and HbA1C.  
 
Material and Methods 
Participants 
Participants were identified from the 10,001 Dalmatians research programme, originating 
from the sub-cohort recruited from the island of Vis in Croatia. A total of 1,029 subjects were 
initially recruited, aged 18–93 years, who were recruited from the villages of Vis and Komiza 
during 2003 and 2004 within a larger genetic epidemiology study (15,16,17). In the original 
study, the only eligibility criterion was being 18 years or older. sTfR and ferritin levels were 
 
 
measured in 774 subjects, of whom, 49 subjects with missing values for covariates (age, 
fibrinogen, glycosylated hemoglobin, smoking and alcohol consumption, body mass index 
and history of cardiometabolic disease) were excluded leaving a study population of 725 
people. Distribution of exposure, adjustment variables and outcomes were similar in people 
with and without missing data with the exception of fibrinogen levels which were higher in 
people without missing data.  Ethical approval was issued by Multi-centre research ethics 
committee for Scotland (MREC) under designation MREC 01/0/71, and all participants gave 
written informed consent. 
 
Clinical and anthropometric measurements 
Anthropometric measurements, included height measured using a stadiometer, weight and 
waist circumference measurement (measured half-way between the lowest rib and iliac crest). 
Blood pressure was measured in a seated position, after at least 5 minutes of rest. Two 
measurements were made, and only the second one recorded, in order to reduce the “white 
coat” effect. Menopausal status was defined on the basis of self-report  with pre-menopausal 
status defined by continuing menstruation and post-menopausal status by lack of 
menstruation For physical activity it was used a self-perceived report on the physical 
activities at work and at leisure on a 4-point rating scale (sitting, light, moderate, and hard).  
 
Biochemical measurements 
Blood samples were taken after overnight fasting. Classical biochemical analyses of the 
blood sample included triglycerides by using UV photometry with glycerolphosphate-oxidase 
(GPO PAP)(Olympus kit OSR60118); HDL cholesterol – homogeneous enzyme method with 
modified polyethylene glycol and acyclohexane-sulphate (Olympus kit OSR6195); glucose – 
UV hexokinase photometry; HbA1C (whole-blood sample) – cation exchange, 
 
 
immunochemistry electrophoresis and affinity linking, that is compatible with DCCT/UK 
PDS standard. The measurements of HbA1C and glucose were performed using Olympus kit 
OSR6192, OSR 6121 and OSR6221. Manufacturer’s reagents were used, with their internal 
quality control (ODC003 or ODC004 for glucose, and ODC022 for HbA1C). Fibrinogen was 
measured by the Clauss method using an MDA 180 coagulometer (Biomerieux, Marcy 
l’Etoile, France) with reagents from the manufacturer. The calibrant used was the 8th British 
Standard (NIBSC). Electrochemiluminescence immunoassay (Roche) was used to measure 
ferritin, Tina-quant® immunoturbidometry (Roche) for sTfR. The laboratory was ISO 
accredited and daily internal controls were performed (calibrator 66300). Repeated 
measurements of the sub-set of samples provided very high agreement (kappa 0.92 for the 
lowest pair of estimates). The coefficient of variation was less than 5% for each biochemical 
measurement.  The biochemical assays were conducted by using an OLYMPUS AU400 
chemistry immuno analyzer. Insulin resistance was estimated by homoeostatic model 
assessment using the formula: glucose levels [mmol/L] X insulin mU/L / 22.5 (18).  
 
 
 
 
Metabolic syndrome 
Cut- points from the international consensus definition for metabolic syndrome were used as 
follows(19): triglycerides ≥ 1.7 mmol/L, HDL-C <1.0 mmol/L in men and <1.3 in women, 
glucose ≥ 5.6 mmol/L (or drug treatment for elevated glucose), systolic blood pressure ≥ 130 
mm/Hg and or/ diastolic blood pressure ≥ 85 mm/Hg (or antihypertensive drug treatment), 
and waist circumference ≥ 94cm in men and ≥ 80cmin women. Since information on lipid-
lowering medications was not available to complement the component of high triglycerides, 
the MetS definition used in this study represents a modified definition of the international 
consensus’ criteria.  Metabolic syndrome was defined as the presence of three or more 
variables meeting the definitions above.  
 
Data analysis 
The analyses were stratified by sex/menopausal status and by adjusting for group of 
sex/menopausal status (premenopausal women as reference/ postmenopausal women/ men) in 
analyses of the whole cohort. All continuous study variables were summarised as median 
(interquartile ranges) by sex/menopausal status and differences were tested using the Mann-
Whitney U test. Logistic regression models were used to describe the associations between 
sTfR and ferritin as exposure variables with MetS and its components as outcome variables. 
sTfR and ferritin were used as continuous variables in terms of standard deviation units of 
their log-transformed levels (Z scores or standardized values)  to facilitate interpretation of 
odds ratios. Odds of each outcome are therefore described for each standard deviation in log-
transformed iron marker. Multivariable models with age, levels of fibrinogen, smoking ( 
never smoker, ex-smoker, current smoker), alcohol consumption (no/yes), and body mass 
index (BMI) as covariates were used to investigate whether the associations were 
 
 
independent of these potential confounding factors. This set of confounding factors was 
chosen on the basis of possible influence of acute phase or subclinical inflammation in terms 
of fibrinogen levels (20,21), and general adiposity on levels of iron markers and/or outcome 
variables. In the case of the associations with waist circumference, BMI was included as 
covariate to investigate the role of central adiposity reflected by waist independently of the 
effect of general adiposity reflected by BMI. Relationships between measures of iron status 
and insulin resistance and HbA1C were described using Pearson correlation, and multiple 
linear regression analyses used to adjust for potential confounders as listed above with 
additional adjustment for treatment with insulin and/or hypoglycaemic drugs (yes/no). 
Evaluation of non-linear relationships with insulin resistance was performed using ANOVA 
and ANCOVA to describe the association between tertiles of iron markers and HOMA-IR 
values tests.  The normality of distributions was assessed using histograms and Kolmogorov-
Smirnov tests. For the linear regressions, Pearson correlation and ANCOVA analyses, 
transformed values of skewed variables were used as follows: logarithm of sTfR, ferritin, 
HOMA-IR values, body mass index and fibrinogen values; square of age and square root of 
glycosylated haemoglobin. The above set of arithmetic functions allowed the best 
approximation to normal distribution for each variable. Self-reported cardiovascular disease 
(heart attack, stroke) and diabetes, and self-reported physical activities at work and at leisure 
(sitting [reference], light, moderate, and hard), were additionally used as covariates in 
sensitivity analyses. In order to avoid collinearity, treatment with insulin and/or 
hypoglycemic drugs (yes/no) was not considered in the multivariable model when diabetes 
was used as covariate. A P value < 0.05 was considered statistically significant. Data were 
analyzed using Stata version 11.0 (StataCorp). 
 
 
 
 
Results 
The study encompassed a total of 725 subjects, stratified in three groups by sex/menopausal 
status (Table 1). Men had higher values of ferritin than women, while postmenopausal 
women had higher values of ferritin than premenopausal women. Postmenopausal women 
had significantly higher levels of sTfR than men, while the comparison with pre-menopausal 
women was not significant (Table 1). HOMA-IR was higher in men and postmenopausal 
women than among pre-menopausal women with a similar pattern observed for MetS 
components. Prevalence of high WC was above 60 % in all groups (Table 1). Prevalence of 
MetS was higher in post-menopausal women than in men and pre-menopausal women (Table 
1).  
The prevalence of MetS in the whole population was 48.7%, and 34.3% among individuals 
without cardiometabolic disease (cardiovascular diseases and/or diabetes) (data not shown). 
There was no statistically significant association between standardized values of sTfR and 
MetS and its components in any of the sex/menopausal status groups (Table 2) or in the 
whole sample (Table 3). Since high prevalence of some components could limit the power of 
the study to detect an association with sTfR, we additionally conducted linear regression 
analysis between log-sTfR and log-transformed values of WC, HDL-C, glucose, 
triglycerides, SBP and DBP. The unadjusted linear regressions showed only association with 
log-glucose (βeta= 0.18 [0.002 to 0.37], P=0.047) and log-WC (βeta= 0.12 [0.02 to 0.22], 
P=0.015) in men, log-triglycerides in premenopausal women (βeta= 0.32 [0.01 to 0.63], 
P=0.041), and log-WC (βeta= 0.15 [0.05 to 0.25], P=0.002) in postmenopausal women, but 
after adjustments there were no significant associations (Supplementary table 1). Further 
adjustment for treatment with insulin and/or hypoglycemic drugs in associations with 
 
 
glucose, and for anti-hypertensive medication in associations with SBP and DBP, did not 
alter the significance of the above findings (data not shown).  
 
Standardized values of ferritin were significantly associated with higher odds of having MetS 
components (except high blood pressure) in men, in unadjusted models and adjusting for age, 
fibrinogen levels, alcohol intake, and smoking (Table 2). Ferritin was significantly associated 
with MetS in men and postmenopausal women (Table 2). In the whole sample, the adjusted 
associations found for ferritin and MetS and its components were similar to those reported in 
men (Table 3).  
In a separate analysis for women adjusting for menopausal status, sTfR was not associated 
with MetS or its components, and ferritin was independently associated with high 
triglycerides and MetS (Supplementary table 2).  
 
We performed additional evaluation of associations between MetS and its components and 
standardized values of sTfR/ferritin ratio Supplementary table and 3). A lower ratio reflects 
higher iron status on the basis of increased iron stores regarding low iron demand in tissues. 
In general the associations for sTfR/ferritin ratio were similar to those described for ferritin 
(Table 2). 
 
STfR levels correlated positively with insulin resistance in postmenopausal women and men, 
and this relationship remained statistically significant in linear regression analyses (Figure 1) 
with associations in two of the three strata remaining significant after adjusting for 
covariates: postmenopausal women (βeta= 0.34 [0.05 to 0.63], P=0.020) and men (βeta= 0.44 
[0.14 to 0.75], P=0.004) (see also Supplementary table 4). On the other hand there was a 
borderline statistically significant correlation between ferritin and HOMA-IR in men (Figure 
 
 
1) which did not persist after adjustments (Supplementary table 4). In the whole sample, sTfR 
levels were associated with insulin resistance after adjustment for covariates including 
sex/menopausal status (P<0.05), but no association was observed for ferritin in similar 
analyses (Supplementary table 4). The relationship between sTfR and HOMA-IR was driven 
by the relationship between sTfR and insulin levels which were similarly significant 
(Supplementary table 4), whereas adjusted associations with glucose levels were not 
statistically significant (Supplementary table 1).  
 
We also evaluated potential non-linear associations between ferritin and insulin resistance 
and found that mean HOMA-IR in the highest tertile of ferritin was significantly higher than 
for the lowest tertile even after adjustment for covariates (Supplementary figure 1).  
In the unadjusted analysis, HbA1C, a marker of longer-term glucose metabolism, was 
significantly associated with sTfR in men and with ferritin in the whole sample, but after 
adjustments there were no significant independent associations (Supplementary table 5).   
 
We additionally used diabetes, cardiovascular disease and categories of physical activity as  
covariates in the adjustment models, but the estimates of the associations described above 
between the iron markers, MetS, insulin resistance and HbA1C and the statistical significance 
did not change substantially (Supplementary table 6).  
 
Supplementary tables 7 and 8 show the effect of additional adjustment for BMI on the 
association between iron markers and MetS and its components. All of the initial significant 
associations remained significant after adjustment for BMI, with the exception of the 
associations between ferritin and increased waist circumference in men and the whole 
sample.  
 
 
 
Discussion 
 
In this study of a population with high prevalence of metabolic syndrome we report three key 
findings. First, sTfR levels were associated with insulin resistance but not with MetS. 
Secondly, the positive association between sTfR and HOMA-IR was independent of 
covariates. Third, iron stores (measured as serum ferritin) were non-linearly associated with 
insulin resistance. This set of findings suggests that different iron related proteins are 
involved in cardiometabolic risk by separate underlying mechanisms. 
 
The lack of association between sTfR levels and MetS is consistent with findings in different 
studies of different sizes ranging from 155 to 1,969 subjects (supplementary table 9). A 
Finnish study of middle-aged subjects from the general population also found no significant 
association when controlling for confounding factors (supplementary table 9) (12). In the 
same study, levels of sTfR levels were significantly higher in adjusted analyses (12). A small 
study reported lower levels of sTfR in subjects with MetS in a sex-stratified analysis but no 
additional adjustments were conducted (22)(supplementary table 9). A significant positive 
age-sex adjusted correlation of sTfR with waist circumference but no evidence of a 
relationship with HDL-C and triglyceride levels in participants from the EPIC-Postdam study 
have also been described (13) (supplementary Table 9).  Diastolic blood pressure and 
triglycerides increased across quartiles of sTfR but no association was found with waist 
circumference, LDL-C, HDL-C, systolic blood pressure and fasting glucose levels in 1,262 
women after adjustment for covariates (14) (supplementary table 9).  Different adjustments, 
statistical approaches and discrepancies in methods measuring sTfR concentrations could 
contribute to the heterogeneity of results from different studies. Various commercial sTfR 
 
 
assays give disparate values because of the lack of an international standard.  For instance, 
Hamalainen et al. reported similar sTfR levels (mean 2.9 mg/L) and prevalence of MetS 
(48% in men and 52% in women) to those we report (12). Very high sTfR levels (mean 9.09 
mg/L) with lower prevalence of some MetS components (high WC 31%, low HDL 43%) 
were described by Aderibigbe et al (14). Meanwhile, Montonen et al. reported lower median 
sTfR levels across ferritin quintiles between 1.0 and 1.9 mg/L (13). In addition, it is 
important to note that the above studies included diverse populations in Europe and South 
Africa which may have influenced differences in association patterns, sTfR levels and 
prevalence of MetS components. 
 
Our finding of a positive association between sTfR and insulin resistance in postmenopausal 
women and men in our study is consistent with two previous studies by Fernandez-Real et al. 
(23) and Huth et al.(24). Fernandez-Real et al. described an inverse association between sTfR 
levels and insulin sensitivity estimated by minimal modeling in 221 Spanish individuals (97 
non-obese with normal glucose tolerance, 36 with impaired glucose tolerance and 88 with 
type 2 diabetes)(23).There was no evidence of associations between sTfR and fasting glucose 
or insulin but positive correlations of sTfR with values of glucose and insulin during an oral 
glucose tolerance test were reported. We report similar findings toHuth et al who found that  
sTfR levels were significantly and positively correlated with HOMA-IR in 2893 participants 
of the population-based Cooperative Health Research in the Region of Augsburg (KORA) F4 
study (Germany)(24). In contrast, Arija et al. did not find significant correlation between 
sTfR and HOMA-IR adjusting for sex, age and BMI either in Spanish non-diabetic 
individuals (n=302) as in a mixed group of those non-diabetic  plus non-diabetic subjects 
who later developed diabetes (n=153)(25). The relationship between sTfR and glucose 
metabolism might be easier to identify in the postprandial than in fasting state since 
 
 
Fernandez-Real reported correlation with glucose concentrations after an oral glucose test 
tolerance test (23). In addition an insulin-sensitizing intervention of dietary change combined 
with exercise was associated with decreasing sTfR levels in obese individuals (26). We found 
that additional adjustment for physical activity did not substantially affect the non-significant 
associations of sTfR with MetS and its components but acknowledge that our measurement 
of physical activity is imperfect. A significant association between presence of transferrin 
receptor gene polymorphisms (rs3817672, 210AG, S142G) and type 2 diabetes has been 
described (27). In addition, individuals with 210A--G TfR gene polymorphism showed 
higher sTfR levels which correlated positively with glucose levels whereas in non-carriers 
there was no relationship between those markers (27). These associations with 
polymorphisms were not confirmed in genetic consortia databases (28).However, other 
studies have found other SNPS linked to both type 2 diabetes and sTfRs. For instance, 
significant associations have been observed for loci in TPMRSS6 with sTfR (P = 3.47×10(-6)) 
and type 2 diabetes risk (29).These findings imply that a common third factor might influence 
both circulating sTfR levels and diabetes susceptibility. 
 
Although the finding of a  positive association between sTfR and insulin resistance could 
suggest that low iron status, in terms of high sTfR, may also be associated with 
cardiometabolic risk, it appears unlikely given the absence of concomitant association with 
MetS or its components in this cross-sectional study. A potential explanation is the effect of 
insulin on sTfR levels.  Insulin upregulates erythropoiesis (30), of which sTfR is a surrogate. 
sTfR represents a valuable quantitative assay of marrow erythropoietic activity as well as a 
marker of tissue iron deficiency (31). Marrow erythropoietic activity appears to be the most 
important determinant of sTfR levels, causing variations up to 8 times below and up to 20 
times above average normal values (31). The erythroblasts rather than reticulocytes are the 
 
 
main source of serum sTfR. Soluble TfR levels are decreased when erythropoietic activity is 
low, and are increased in situations of hemolysis or ineffective erythropoiesis (31). As insulin 
has been described to upregulate erythropoiesis (30), it could be that this action of insulin 
remains sensitive in contrast to peripheral insulin resistance in the liver or in the muscle (the 
classical insulin sensitive tissues). If this is the case, sTfR might appear to be spuriously 
elevated and would not reflect the insulin sensitivity in other tissues. In addition, up-
regulation in the expression of transferrin receptors by insulin via a hypoxia inducible factor, 
as observed in human hepatic cells (HepG2)(32) is an alternative explanation.   
 
We identified differences by sex and menopausal status in the relationship of ferritin with 
MetS and its components since significant associations were found in men and 
postmenopausal women, but not in premenopausal women in our study showed. 
Theoretically, in men and postmenopausal women the relationship between ferritin and 
cardiometabolic risk might be more obvious due to higher iron accumulation than in women 
who lose iron during menstruation. This is in line with studies describing no association 
between ferritin and MetS in premenopausal women (33, 34). However, several studies have 
also reported significant relationship between ferritin and MetS in premenopausal women 
(35,36,37,38).Threshold effects do not appear to contribute to the  discrepancy in relationship 
since studies had  comparable ferritin concentrations and MetS prevalence (  10%) among 
pre-menopausal women regardless of whether or not an association was described. Statistical 
power could explain the discrepant findings because most of the studies describing 
association had larger sample sizes for premenopausal women than those with no association. 
The relationship between insulin resistance and ferritin appeared to demonstrate a threshold 
effect when comparing the highest levels of ferritin vs. the lower (tertiles 1 and 2) in the 
whole group of subjects.  
 
 
 
Neither ferritin nor sTfR were associated with HbA1c whether or not diabetes was included 
as a covariate in the models. Our finding is consistent with the lack of association between 
ferritin and HbA1C reported in the 3876 participants of NHANES III (1988-1994)(39). 
Previously, Fernandez-Real et al.(21) and Rajpathak et al. (40) described significant weak 
correlations (r=0.14 and r=0.12) between sTfR and HbA1C in 221 men and 560 overweight 
individuals respectively. However, in the first study the correlation was unadjusted, and the 
second only adjusted for age and sex, and it is unknown if metabolic and adiposity covariates 
might have attenuated the relationships. It is of note that the associations between sTfR and 
HbA1C do not appear to have been evaluated using robust multivariate analyses in the 
existing literature. Therefore, further population-based studies are needed to confirm absence 
of association between HbA1C and markers of iron metabolism after multivariate adjustment 
in general populations. 
 
In the present study we presented adjusted associations between the iron markers, MetS and 
its components with and without BMI as covariate. MetS is common in overweight and obese 
individuals (41) and BMI might confound or mediate the relationship between iron 
metabolism and MetS We found that only the association between ferritin and waist 
circumference was markedly attenuated after adjustment for BMI.  Although this might have 
been expected given the high correlation between waist circumference and BMI and other 
study reported similar attenuation (42), another study reported a significant association 
between ferritin and increased waist circumference independently of BMI adjustment (43). 
This latter study had a larger sample size with higher ferritin levels.  In our study, the 
significant associations between ferritin, MetS (in men and premenopausal women), high 
 
 
glucose and triglycerides and low HDL-C in men appear to be independent of BMI and other 
covariates.  
 
 
To the best of our knowledge, the present study is the first to investigate the association 
between sTfR and both MetS and insulin resistance by using a robust multivariable analysis. 
We also have extended the finding by Hamalainen et al. describing the absence of significant 
relationship between STfR and MetS by performing additional adjustments for BMI, alcohol 
consumption, cardiovascular disease and diabetes. In addition previous studies of the 
association between ferritin and sTfR and cardiometabolic risk may have provided biased 
results as a consequence of not adjusting for prevalent cardiometabolic disease. Concomitant 
chronic disease can influence iron status and reverse causality might lead to overestimation of 
the association between iron markers and MetS. Key limitations of our study include of the 
relatively small number of pre-menopausal women and the inability to adjust for hepatic 
dysfunction since markers such as transaminases were not measured in the original study. In 
the original project there were no specific questions about use of lipid-lowering medications 
and therefore associations with components of low HDL-C and high triglyceride could be 
underestimated since these components did not include individuals with prescribed 
medication that might affect these values. The cross-sectional design of the study means that 
it is not possible to provide evidence of a causal relationship between iron status and cardio-
metabolic risk factors. In addition, no adjustment for multiple testing was performed and 
some findings may be due to chance. For the present study, we used the sample of subjects 
with available measurements of exposure, outcome and adjustment variables and have not 
performed a power calculation. However, our sample as a whole is relatively large sample in 
comparison with previous studies but may have had limited power to detect small effects. 
 
 
Fibrinogen levels were higher in the selected subjects for this analysis than in the non-
selected participants from the Croatia/Vis study, and this was the only difference in the study 
variables. It is not feasible to determine if this difference might have influenced the findings 
since an analysis of data for the excluded subjects would not be reliable given the small 
sample size and a large proportion of missing values. The difference in fibrinogen levels may 
also be a finding by chance due to the multiple testing. The nature of multivariable modelling 
means that people with missing data are excluded.  For clearer and more coherent 
comparisons, the present study provides unadjusted and adjusted estimates using the sub-
group with complete data.  
 
In conclusion, our study found that sTfR levels are associated with insulin resistance but not 
with MetS, independently of age, subclinical/chronic inflammation, smoking and alcohol 
habits, glycosylated hemoglobin, and cardiometabolic disease, in a population with a high 
prevalence of MetS and abdominal obesity. It is possible that sTfR levels are a poor marker 
of erythropoiesis or iron metabolism in subjects with insulin resistance or hyperinsulinemia, 
and are spuriously elevated and therefore not associated with MetS or its components. We 
conclude that there is a complex relationship between markers of iron status and 
cardiometabolic risk, with inconsistent associations with different markers. 
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 Table 1. Distribution of iron status and cardiometabolic risk by sex and menopausal status 
 Premenopausal 
women 
Postmenopausal 
women 
Men P values 
    Premenopausal vs 
postmenopausal 
women 
Men vs. 
premenopausal 
women 
Men vs. 
postmenopausal 
women 
n 151 290 284    
Age (years) 40 (33-47) 67(57-74) 57 (46-68.7) < 0.001 < 0.001 < 0.001 
BMI (kg/m2) 26.6(21.6-27) 28.3(25.4-30.9) 27.6(25.2-29.6) < 0.001 < 0.001 0.013 
Ferritin(µg/L) 25.5 (12-45.9) 65.9 (38.6-102.2)) 141.3 (90.5-233.7) < 0.001 < 0.001 < 0.001 
sTfR (mg/L) 3.19 (2.63-4.05) 3.17 (2.73-3.90) 3.07 (2.62-3.68) 0.758 0.069 0.038 
Glucose  (mmol/L) 5.0(4.6-5.4) 5.6(5.0-6.2) 5.5(5.0-6.1) < 0.001 < 0.001 0.504 
TG (mmol/L) 1.2(0.9-1.5) 1.5(1.1-2.0) 1.5(1.1-2.3) < 0.001 < 0.001 0.542 
HDL-C (mmol/L) 1.16(1.09-1.25) 1.14(0.98-1.23) 1.13(0.96-1.22) 0.011 0.001 0.410 
SBP (mmHg) 118(108-128) 145(130-161) 136.7(122.6-150) < 0.001 < 0.001 < 0.001 
DBP (mmHg) 75(68-80) 81.5(75-89) 81.2(75-89) < 0.001 < 0.001 0.820 
WC (cm) 83(76.9-91.5) 99.2(91.7-105.4) 98.3(92-105.1) < 0.001 < 0.001 0.403 
Insulin mU/L 5.0(4.0-8.0) 7.0(5.0-11) 6.0(4.0-9.0) < 0.001 < 0.001 0.147 
HOMA-IR 1.17(0.78-1.89) 1.69(1.06-2.93) 1.58(1.01-2.60) < 0.001 < 0.001 0.141 
HbA1C(%) 5.1(4.9-5.4) 5.5(5.2-5.7) 5.2(5.0-5.6) < 0.001 < 0.001 < 0.001 
Fibrinogen (g/L) 3.5(2.9-4.0) 3.9(3.4-4.5) 3.5(2.9-4.1) < 0.001 0.714 < 0.001 
MetS and its 
components n(%) 
      
High blood 
pressure¶ 
43(28.3) 237(81.7) 198(69.7) < 0.001 < 0.001 0.001 
High glucose † 27(17.8) 148(51.0) 131(46.1) < 0.001 < 0.001 0.208 
Low HDL-C 137(90.7) 277(95.5) 82(28.9) 0.040 <0.001 <0.001 
High triglycerides 25 (16.6) 118(40.7) 117(41.2) < 0.001 < 0.001 0.902 
High WC 94 (62.3) 278(95.9) 191(67.3) < 0.001 0.296 < 0.001 
MetS 51(33.8) 257(88.6) 144(50.7) < 0.001  0.001 <0.001 
Smoking n(%)       
Yes 64(42.4) 47(16.2) 85(29.9)    
No 58(38.4) 184(63.4) 73(25.7)    
Ex-smoker 29(19.2) 59(20.3) 126(44.4) < 0.001 < 0.001 < 0.001 
Alcohol consumption 
n(%) 
 
79(52.3) 
 
108(37.2) 
 
230(81) 
 
0.002 
 
< 0.001 
 
< 0.001 
Cardiovascular 
disease n(%) 
12(7.9) 150(51.7) 102(35.9)  
< 0.001 
 
< 0.001 
 
< 0.001 
Diabetes n(%) 3(2.0) 27(9.3) 20(7.0) 0.002 0.017 0.201 
       
Data are median (interquartile range) or n(%). Comparison between groups by Mann-Whitney U and 2 test. BMI, body mass index. sTfR, soluble transferrin receptor. TG, 
triglycerides. SBP, systolic blood pressure. DBP, diastolic blood pressure. WC, waist circumference. HDL-C, HDL cholesterol. MetS, metabolic syndrome. HOMA-IR, 
homeostatic model assessment insulin resistance. † Includes additionally individuals who reported current use of oral hypoglycemic medications or insulin 
regardless of fasting glucose values.¶ Includes additionally individuals who reported current use of antihypertensive medications regardless of blood 
pressure values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2. Odds ratios(95% CI)  for metabolic syndrome and its components per sex/menopausal-specific 
SD of the iron markers in the study subjects categorised by sex and menopausal status 
 Z score log-sTfR  Z score log-ferritin 
 Non-adjusted Adjusted* Non-adjusted Adjusted* 
Premenopausal 
women 
    
High glucose † 1.35 (0.87-2.09) 1.23 (0.77-1.95) 0.89 (0.59-1.36) 1.01 (0.65-1.58) 
Low HDL-C  1.18 (0.71-1.96) 1.14 (0.68-1.90) 0.95 (0.54-1.65) 0.96 (0.51-1.79) 
High TG 1.35 (0.87-2.12) 1.29 (0.80-2.08) 1.51 (0.96-2.39) 1.51 (0.94-2.44) 
High BP¶ 1.35 (0.91-1.99) 1.29 (0.84-1.92) 0.95 (0.66-1.36) 0.96 (0.66-1.40) 
High WC 1.07 (0.77-1.49) 1.01 (0.71-1.43) 0.79 (0.56-1.11) 0.79 (0.54-1.15) 
MetS 1.32 (0.90-1.92) 1.21 (0.81-1.79) 1.13 (0.80-1.59) 1.24 (0.85-1.80) 
Postmenopausal 
women 
    
High glucose † 1.08 (0.86-1.37) 1.009 (0.78-1.29) 1.23 (0.97-1.56) 1.20 (0.94-1.52) 
Low HDL-C  1.22 (0.66-2.28) 1.45 (0.74-2.84) 0.76 (0.41-1.40) 0.81 (0.45-1.45) 
High TG 0.99 (0.78-1.25) 0.97 (0.75-1.24) 1.26 (0.98-1.61) 1.28 (0.99-1.64) 
High BP¶ 1.13 (0.83-1.56)     0.94 (0.66-1.34) 1.14 (0.85-1.52) 1.08 (0.77-1.51) 
High WC 1.10 (0.59-2.03) 1.00 (0.50-1.97) 1.10 (0.63-1.94) 0.98 (0.51-1.90) 
MetS 0.99 (0.69-1.43) 0.83 (0.54-1.26) 1.65 (1.17-2.31) 1.65 (1.11-2.46) 
Men     
High glucose † 1.20 (0.94-1.52) 1.10 (0.85-1.41) 1.37 (1.07-1.75) 1.42 (1.10-1.84) 
Low HDL-C  0.93 (0.72-1.21) 0.94 (0.72-1.24) 1.61 (1.21-2.15) 1.60 (1.19-2.15) 
High TG 1.03 (0.81-1.30) 1.07 (0.84-1.38) 1.69 (1.29-2.21) 1.71 (1.29-2.26) 
High BP¶ 1.13 (0.87-1.46) 0.97 (0.72-1.29) 1.15 (0.89-1.48) 1.21 (0.91-1.61) 
High WC 1.30 (1.00-1.70) 1.16 (0.87-1.55) 1.53 (1.18-1.98) 1.62 (1.22-2.15) 
MetS 1.05 (0.83-1.33) 0.95 (0.74-1.22) 1.90 (1.44-2.50) 2.02 (1.51-2.70) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker) and alcohol consumption (no/yes). † 
Includes additionally individuals who reported current use of oral hypoglycemic medications or insulin 
regardless of fasting glucose values.¶ Includes additionally individuals who reported current use of 
antihypertensive medications regardless of blood pressure values. TG, triglycerides. BP, blood pressure.. 
WC, waist circumference.  59 cases were omitted because in the category of ex-smoker all of the 
subjects had high WC.  HDL-C, HDL cholesterol. MetS, metabolic syndrome. Significant associations are 
show in bold (P<0.05). 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 3. Odds ratios(95% CI)  for metabolic syndrome and its components per SD  of iron markers in the whole sample 
 Z score log-sTfR  Z score log-ferritin Z score log-sTfR/ferritin ratio 
 Non-adjusted Adjusted* Non-adjusted Adjusted* Non-adjusted Adjusted* 
High glucose 
† 
1.11 (0.95-1.29) 1.10 (0.92-1.30) 1.48 (1.27-1.74) 1.31 (1.06-1.61) 0.73 (0.62-0.85) 0.83 (0.68-1.02) 
Low HDL-C  1.16 (0.98-1.36) 0.98 (0.76-1.25) 0.46 (0.38-0.56) 1.40 (1.06-1.84) 2.07 (1.69-2.53) 0.75 (0.57-0.98) 
High TG 1.02 (0.88-1.19) 1.05 (0.89-1.24) 1.71 (1.44-2.03) 1.67 (1.34-2.09) 0.63 (0.53-0.75) 0.68 (0.55-0.83) 
High BP¶ 1.09 (0.93-1.28) 1.05 (0.88-1.27) 1.52 (1.30-1.78) 1.14 (0.90-1.44) 0.71 (0.61-0.84) 0.92 (0.74-1.14) 
High WC 1.16 (0.97-1.39)  1.02 (0.84-1.24) 1.09 (0.91-1.29) 1.30 (1.01-1.68) 0.96 (0.81-1.15) 0.82 (0.65-1.04) 
MetS 1.09 (0.94-1.27) 0.97 (0.82-1.15) 1.41 (1.21-1.65) 1.92 (1.52-2.43) 0.76 (0.65-0.88) 0.60 (0.49-0.75) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker), alcohol consumption (no/yes), and sex/menopausal status (premenopausal 
women/ postmenopausal women/men). † Includes additionally individuals who reported current use of oral hypoglycemic medications 
or insulin regardless of fasting glucose values .¶ Includes additionally individuals who reported current use of antihypertensive 
medications regardless of blood pressure values. TG, triglycerides. BP, blood pressure.. WC, waist circumference. HDL-C, HDL 
cholesterol. MetS, metabolic syndrome. Significant associations are show in bold (P<0.05). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 1. Pearson correlations between insulin resistance and iron markers.  
 
 Supplementary table 1. Beta coefficients (95% CI) of relationship 
between log-sTfR and log-transformed values of variables related to 
MetS components 
 log-sTfR  
Premenopausal 
women 
Non-adjusted Adjusted* 
log-glucose  0.03 (-0.07 to 0.15) 0.01 (-0.09 to 0.12) 
log- HDL-C  -0.006 (-0.15 to 0.14) 0.008 (-0.14 to 0.16) 
log-TG 0.32 (0.01 to 0.63) 0.26 (-0.04 to 0.56) 
log-SBP 0.07 (-0.01 to 0.17) 0.04 (-0.04 to 0.12) 
log-DBP 0.01 (-0.07 to 0.11) -0.002 (-0.08 to 0.08) 
log- WC 0.06 (-0.02 to 0.15) 0.007 (-0.03 to 0.05) 
Postmenopausal 
women 
  
log-glucose  0.06 (-0.12 to 0.24) -0.04 (-0.22 to 0.14) 
log- HDL-C  0.04 (-0.08 to 0.17) 0.07 (-0.06 to 0.21) 
log-TG 0.01 (-0.37 to 0.40) -0.14 (-0.53 to 0.23) 
log-SBP 0.10 (-0.03 to 0.25) -0.007 (-0.13 to 0.12) 
log-DBP -0.01 (-0.12 to 0.09) -0.06 (-0.17 to 0.04) 
log- WC 0.15 (0.05 to 0.25) 0.05 (-0.004 to 0.10) 
Men   
log-glucose  0.18 (0.002 to 0.37) 0.09 (-0.09 to 0.27) 
log- HDL-C  -0.03 (-0.18 to 0.11) -0.02 (-0.18 to 0.12) 
log-TG 0.33 (-0.14 to 0.81) 0.34 (-0.13 to 0.82) 
log-SBP 0.10 (-0.03 to 0.25) -0.01 (-0.14 to 0.11) 
log-DBP 0.05 (-0.07 to 0.18) 0.01 (-0.11 to 0.14) 
log- WC 0.12 (0.02 to 0.22) 0.01 (-0.02 to 0.06) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker), alcohol 
consumption (no/yes), and BMI. Multivariable adjusted analyses were 
performed on transformed values of skewed variables: logarithm of sTfR , 
ferritin ,  body mass index  and fibrinogen values;  square of age. . TG, 
triglycerides. SBP, systolic blood pressure. DBP, diastolic blood pressure. 
WC, waist circumference. HDL-C, HDL cholesterol. Significant associations 
are shown in bold (P<0.05). 
 
 
 
Supplementary table 2. Odds ratios(95% CI)  for metabolic syndrome and its components per  SD of iron markers in women of the 
study  
 Z score log-sTfR  Z score log-ferritin Z score log-sTfR/ferritin ratio 
Women       
 Non-adjusted Adjusted* Non-adjusted Adjusted* Non-adjusted Adjusted* 
High glucose † 1.09 (0.90-1.33) 1.07 (0.85-1.36) 1.53 (1.24-1.88) 1.12 (0.88-1.43) 0.72 (0.59-0.89) 0.93 (0.73-1.18) 
Low HDL-C  1.17 (0.81-1.69) 1.16 (0.84-1.61) 1.05 (0.71-1.55) 0.83 (0.52-1.31) 1.00 (0.68-1.49) 1.23 (0.79-1.91) 
High TG 1.05 (0.86-1.28) 1.02 (0.80-1.30) 1.66 (1.32-2.08) 1.41 (1.08-1.83) 0.67 (0.53-0.84) 0.76 (0.59-0.99) 
High BP¶ 1.10 (0.90-1.34) 1.10 (0.85-1.42) 1.74 (1.41-2.14) 1.03 (0.77-1.36) 0.66 (0.54-0.81) 1.01 (0.77-1.32) 
High WC 1.01 (0.78-1.31) 0.90 (0.67-1.20) 1.53 (1.18-1.95) 0.90 (0.57-1.42) 0.72 (0.56-0.91) 0.99 (0.67-1.47) 
MetS 1.06 (0.86-1.30) 1.02 (0.78-1.30) 2.22 (1.77-2.80) 1.55 (1.13-2.13) 0.55 (0.44-0.68) 0.73 (0.54-0.99) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker), alcohol consumption (no/yes), BMI and menopause. † Includes additionally 
individuals who reported current use of oral hypoglycaemic medications or insulin regardless of fasting glucose values .¶ Includes 
additionally individuals who reported current use of antihypertensive medications regardless of blood pressure values. TG, triglycerides. 
BP, blood pressure.. WC, waist circumference. HDL-C, HDL cholesterol. MetS, metabolic syndrome. Significant associations are shown 
in bold (P<0.05). 
 
 
 
  
 
Supplementary table 3. Odds ratios(95% CI)  for 
metabolic syndrome and its components per SD of 
the sTfR/ferritin ratio in the study subjects 
categorised by sex and menopausal status 
 Z score log-sTfR/ferritin ratio 
 Non-adjusted Adjusted* 
Premenopausal 
women 
  
High glucose † 1.20 (0.79-1.80) 1.06 (0.68-1.63) 
Low HDL-C  1.11 (0.63-1.96) 1.12 (0.59-2.10) 
High TG 0.83 (0.53-1.29) 0.79 (0.49-1.27) 
High BP¶ 1.15 (0.81-1.63) 1.08 (0.74-1.59) 
High WC 1.21 (0.86-1.70) 1.02 (0.64-1.61) 
MetS 1.01 (0.72-1.41) 0.86 (0.58-1.27) 
Postmenopausal 
women 
  
High glucose † 0.86 (0.68-1.08) 0.86 (0.67-1.10) 
Low HDL-C  1.34 (0.70-2.56) 1.38 (0.72-2.67) 
High TG 0.82 (0.64-1.04) 0.79 (0.61-1.03) 
High BP¶ 0.92 (0.69-1.24) 0.92 (0.64-1.30) 
High WC 0.94 (0.53-1.65) 0.90 (0.39-2.03) 
MetS 0.67 (0.48-0.92) 0.59 (0.39-0.89) 
Men   
High glucose † 0.80 (0.63-1.02) 0.79 (0.61-1.02) 
Low HDL-C  0.64 (0.48-0.85) 0.66 (0.49-0.89) 
High TG 0.64 (0.49-0.83) 0.68 (0.51-0.89) 
High BP¶ 0.91 (0.71-1.17) 0.94 (0.70-1.26) 
High WC 0.75 (0.58-0.96) 0.83 (0.56-1.24) 
MetS 0.59 (0.45-0.77) 0.58 (0.43-0.79) 
*Age, fibrinogen levels, smoking status (yes/no/ex-
smoker), alcohol consumption (no/yes), and BMI. † 
Includes additionally individuals who reported current 
use of oral hypoglycaemic medications or insulin 
regardless of fasting glucose values .¶ Includes 
additionally individuals who reported current use of 
antihypertensive medications regardless of blood 
pressure values. TG, triglycerides. BP, blood pressure.. 
WC, waist circumference. HDL-C, HDL cholesterol. 
MetS, metabolic syndrome. Significant associations are 
shown in bold (P<0.05). 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Supplementary table 4. Adjusted* Beta coefficients (95% CI)  for values of log-HOMA-IR and log-insulin by levels  of iron 
markers in the study subjects 
Independent 
variable  
log-sTfR log-ferritin 
Dependant 
variable  
log-HOMA-IR log-insulin log-HOMA-IR log-insulin 
In     
Premenopausal 
women 
0.07 (-0.12 to 0.27) 0.15 (-0.27 to 0.58) 0.05 (-0.05 to 0.16) 0.09 (-0.14 to 0.33) 
Postmenopausal 
women 
0.34 (0.05 to 0.63) 0.83 (0.23 to 1.43) 0.01 (-0.09 to 0.11) 0.01 (-0.19 to 0.23) 
Men 0.44 (0.14 to 0.75) 0.98 (0.34 to 1.63) 0.01 (-0.09 to 0.11) -0.03 (-0.26 to 0.18) 
All** 0.24 (0.09 to 0.39) 0.54 (0.23 to 0.86) 0.04 (-0.01 to 0.10) 0.06 (-0.06 to 0.19) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker), alcohol consumption (no/yes), treatment with insulin and/or 
hypoglycaemic drugs (yes/no), and BMI. ** Additionally adjusted for sex/menopausal status (premenopausal women 
[reference] / postmenopausal women/men). Multivariable adjusted analyses were performed on transformed values of 
skewed variables: logarithm of sTfR , ferritin , HOMA-IR  values, body mass index  and fibrinogen values;  square of age. 
Significant associations are shown in bold (P<0.05). 
 
 
 
 
 
  
 
 
Supplementary table 5. Beta coefficients (95% CI)  for values of glycosylated haemoglobin (HbA1C) by levels  of iron 
markers in the study subjects 
 log-sTfR  log-ferritin 
 Non-adjusted Adjusted* Non-adjusted Adjusted* 
Premenopausal 
women 
-0.06 (-0.14 to 0.01) -0.06 (-0.14 to 0.01) 0.02 (-0.01 to 0.07) 0.02 (-0.01 to 0.07) 
Postmenopausal 
women 
0.02 (-0.13 to 0.17) -0.04 (-0.17 to 0.08) -0.007 (-0.06 to 0.04) -0.009 (-0.05 to 0.03) 
Men 0.18 (0.03 to 0.33) 0.03 (-0.09 to 0.16) 0.02 (-0.02 to 0.07) 0.001 (-0.04 to 0.04) 
All** 0.01 (-0.05 to 0.09) -0.03 (-0.10 to 0.02) 0.05 (0.01 to 0.08) 0.005 (-0.02 to 0.03) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker), alcohol consumption (no/yes), treatment with insulin 
and/or hypoglycaemic drugs (yes/no), and BMI. * Additionally adjusted for sex/menopausal status (premenopausal 
women [reference] / postmenopausal women/men). Multivariable adjusted analyses were performed on transformed 
values of skewed variables: logarithm of sTfR , ferritin ,  body mass index  and fibrinogen values;  square of age and 
square root(sqrt) of glycosylated haemoglobin. Significant associations are shown in bold (P<0.05). 
 
 
 
 
 
 
 
 Supplementary table 6. Associations* between iron markers and metabolic syndrome, insulin resistance, and glycosylated hemoglobin additionally adjusted 
for physical activity, diabetes and cardiovascular disease 
Independent 
variable  
Z score log-sTfR log-sTfR log-sTfR Z score log-ferritin log-ferritin log-ferritin 
Dependent 
variable 
MetS  
[OR(95%CI)] 
log-HOMA-IR 
[Beta(95%CI)] 
Sqrt-HbA1C 
[Beta(95%CI)] 
MetS  
[OR(95%CI)] 
log-HOMA-IR 
[Beta(95%CI)] 
Sqrt-HbA1C 
[Beta(95%CI)] 
In       
Premenopausal 
women(n=148) 
1.21 (0.79 to 1.87) 0.07 (-0.12 to 0.28) -0.07 (-0.16 to 0.04) 1.45 (0.93 to 2.26) 0.03 (-0.08 to 0.14) 0.02 (-0.01 to 0.07) 
Postmenopausal 
women(n=270)  
0.70 (0.43 to 1.14) † 0.44 (0.13 to 0.75)  0.01 (-0.14 to 0.15) 2.01 (1.25 to 3.23)† -0.02 (-0.13 to 0.08) -0.01 (-0.06 to 0.03) 
Men (n=275) 0.82 (0.59 to 1.10) 0.36 (0.05 to 0.67) -0.02 (-0.15 to 0.10) 2.06 (1.46 to 2.92) 0.03 (-0.07 to 0.13) -0.001 (-0.04 to 0.04) 
All**(n=693) 0.95 (0.78 to 1.16) 0.24 (0.08 to 0.39) -0.03 (-0.10 to 0.03) 2.00 (1.52 to 2.63) 0.03 (-0.03 to 0.09) 0.004 (-0.02 to 0.03) 
*Adjusted for age, fibrinogen levels, smoking status (yes/no/ex-smoker), alcohol consumption (no/yes), diabetes (yes/no), cardiovascular disease(yes/no), 
physical at work (sitting [reference], light, moderate, and hard), physical activity at leisure (sitting [reference], light, moderate, and hard),  and BMI. ** 
Additionally adjusted for sex/menopausal status (premenopausal women [reference] / postmenopausal women/men). Multivariable adjusted analyses were 
performed on transformed values of skewed variables: logarithm of sTfR , ferritin ,  body mass index  and fibrinogen values;  square of age and square root 
(sqrt) of glycosylated haemoglobin. Significant associations are shown in bold (P<0.05). † In postmenopausal women all the cases with diabetes had MetS and 
therefore diabetes was omitted in the model.   
 
 
 
 
 
 
 
Supplementary table 7. Odds ratios(95% CI)  for 
metabolic syndrome and its components per SD of the 
iron markers in the study subjects categorised by sex and 
menopausal status with additional adjustment for BMI 
 Z score log-sTfR  Z score log-ferritin 
 Adjusted* Adjusted* 
Premenopausal 
women 
  
High glucose † 1.23 (0.77-1.99) 1.02 (0.65-1.59) 
Low HDL-C  1.14 (0.69-1.94) 0.94 (0.50-1.77) 
High TG 1.30 (0.80-2.10) 1.56 (0.97-2.53) 
High BP¶ 1.28 (0.84-1.95) 1.00 (0.68-1.46) 
High WC 0.89 (0.60-1.32) 0.87 (0.54-1.42) 
MetS 1.19 (0.78-1.80) 1.35 (0.90-2.02) 
Postmenopausal 
women 
  
High glucose † 0.96 (0.74-1.24) 1.17 (0.91-1.50) 
Low HDL-C  1.39 (0.70-2.72) 0.76 (0.41-1.41) 
High TG 0.89 (0.68-1.15) 1.26 (0.97-1.63) 
High BP¶ 0.89 (0.62-1.29) 1.06 (0.74-1.50) 
High WC 0.61 (0.27-1.39) 0.93 (0.37-2.33) 
MetS 0.73 (0.47-1.15) 1.71 (1.12-2.62) 
Men   
High glucose † 1.08 (0.83-1.40) 1.34 (1.03-1.75) 
Low HDL-C  0.93 (0.70-1.22) 1.56 (1.16-2.11) 
High TG 1.04 (0.80-1.36) 1.60 (1.20-2.12) 
High BP¶ 0.91 (0.67-1.24) 1.04 (0.77-1.39) 
High WC 1.11 (0.70-1.75) 1.27 (0.84-1.86) 
MetS 0.87 (0.66-1.17) 1.78 (1.31-2.42) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker), 
alcohol consumption (no/yes), and BMI. † Includes 
additionally individuals who reported current use of oral 
hypoglycemic medications or insulin regardless of fasting 
glucose values.¶ Includes additionally individuals who 
reported current use of antihypertensive medications 
regardless of blood pressure values. TG, triglycerides. BP, 
blood pressure.. WC, waist circumference.  59 cases were 
omitted because in the category of ex-smoker all of the 
subjects had high WC.  HDL-C, HDL cholesterol. MetS, 
metabolic syndrome. Significant associations are show in 
bold (P<0.05). 
 
 
 
 
 
Supplementary table  8. Odds ratios(95% CI)  for metabolic syndrome 
and its components per SD  of iron markers in the whole sample with 
additional adjustment for BMI 
 
 Z score log-sTfR  Z score log-
ferritin 
Z score log-
sTfR/ferritin 
ratio 
 Adjusted* Adjusted* Adjusted* 
High glucose 
† 
1.08(0.90-1.28) 1.27 (1.03-1.56) 0.85 (0.69-1.04) 
Low HDL-C  0.96 (0.74-1.23) 1.34 (1.01-1.78) 0.77 (0.58-1.01) 
High TG 1.01 (0.85-1.21) 1.62 (1.30-2.03) 0.68 (0.55-0.84) 
High BP¶ 1.02 (0.84-1.23) 1.09 (0.85-1.38) 0.94 (0.75-1.18) 
High WC 0.90 (0.71-1.15) 1.11 (0.80-1.56) 0.88 (0.64-1.19) 
MetS 0.91 (0.75-1.09) 1.93 (1.49-2.49) 0.58 (0.46-0.74) 
*Age, fibrinogen levels, smoking status (yes/no/ex-smoker), alcohol 
consumption (no/yes), BMI and sex/menopausal status (premenopausal 
women/ postmenopausal women/men). † Includes additionally 
individuals who reported current use of oral hypoglycemic medications 
or insulin regardless of fasting glucose values .¶ Includes additionally 
individuals who reported current use of antihypertensive medications 
regardless of blood pressure values. TG, triglycerides. BP, blood 
pressure.. WC, waist circumference. HDL-C, HDL cholesterol. MetS, 
metabolic syndrome. Significant associations are show in bold (P<0.05). 
 
 
 
 
Supplementary table 9.  Studies in general population on sTfR and Metabolic syndrome found in PUBMED and EMBASE by applying the searching “metabolic syndrome OR blood pressure OR 
fasting glucose OR waist circumference OR  triglycerides OR HDL cholesterol” AND “transferrin receptor” (until July/2015). [Only studies in adults were included and  in vitro studies, genetic 
studies and those conducted in specific populations (pregnant women, and patients with diseases) were not included]” 
Authors, 
year of 
publication 
(reference) 
Study Location
/Univers
e  
Study/ 
Year of 
survey 
Age 
range  
(years
) 
Male (%) Total 
sampl
e 
Cardiovascular risk 
markers (outcomes and 
analysis-effect estimate) 
sTfR : 
Continuous  
/categorical-
ordinal 
Association 
 
Adjustments 
         Yes No   
Montonen 
et al., 2012 
(13) 
Cross-
section
al 
Germany
/ 
Potsdam 
populati
on 
Epic -
Potsda
m 
35-65 37.9 1969 WC, HDL-C and TG 
(continuous). Partial 
Pearson Correlations 
Continuous With WC 
(r=0.13),  
(p<0.001).   
With HDL-C and 
TG 
Age and gender 
Aderibigbe 
et al., 2011 
(14) 
Cross-
section
al 
South 
Africa/ 
Populati
on from 
North 
West 
province  
PURE/2
005 
≥35 0 1262 WC, LDL-C, HDL-C, TG, 
DBP, SBP and FG. Levels 
(mean and 95%CI) across 
categories of iron markers. 
Categorical. 
Quartiles. 
With TG: Higher 
levels in 
quartiles 3 and 
4 vs quartile 1. 
With DBP: 
Higher in 
quartile 4 vs 
quartiles 1 and 
2. 
With LDL-C, 
HDL-C, WC, SBP 
and FG. 
Age, BMI, smoking, alcohol 
consumption and CRP.  
Leiva et 
al., 2013 
(20) 
Cross-
section
al 
Chile/Po
pulation 
from 
Talca. 
 
Resear
ch 
Progra
m of 
Risk 
Factors 
for 
Cardiov
ascular 
Disease 
of 
Talca, 
(PIFREC
V) 
45- 
65 
30.9 155 Metabolic syndrome(NCEP 
ATP-III) (dichotomic 
variable) 
Continuous : 
means by 
Metabolic 
syndrome 
(yes/no) 
Lower levels of 
sTfR in subjects 
with MetS 
--------------------- Sex 
Hamalaine
n et 
al.,2012 
(12) 
Cross-
section
al 
Finland/
Middle –
aged 
subjects 
from 
NP/200
3-2004 
52.1 ± 
6.2 
years(
men) 
and 
44.5 766 Metabolic syndrome(NCEP 
ATP-III) and its 
components (dichotomic 
variables) 
Continuous : 
standardized 
means by 
categories of 
Metabolic 
Higher sTfR in 
subjects with 
increased WC 
Metabolic 
syndrome, and 
high blood 
pressure, FG, TG 
and low HDL-C 
Age, sex, hs-CRP, 
smoking and physical 
activity 
Pieksam
aki who 
were 
born in 
1942,19
47,1952,
1957 or 
1962 
52.1 ± 
6.2 
years 
(wom
en) 
syndrome and its 
components  
sTfR, soluble transferrin receptor. WC, waist circumference. LDL-C, LDL cholesterol.  HDL-C, HDL cholesterol. TG, triglycerides. DBP, diastolic blood pressure. SBP, systolic blood pressure. FG, 
fasting glucose.  
 
  
Supplementary figure 1.  Levels of HOMA-IR by sex/menopausal status-specific tertiles of ferritin in 
the whole group.  Levels of HOMA-IR were significantly higher in the highest tertile of ferritin vs. 
tertiles 2 and 1 (P=0.0019 ANOVA / P=0.0139 ANCOVA).  Covariates for ANCOVA were: age, 
fibrinogen levels, HbA1C, smoking status (yes/no/ex-smoker), alcohol consumption (no/yes), treatment 
with insulin and/or hypoglycemic drugs (yes/no), BMI and sex/menopausal status (premenopausal 
women [reference] / postmenopausal women/men). Analyses were performed with transformed values 
of skewed variables: square of age, square root of glycosylated hemoglobin, and logarithm of fibrinogen 
and body mass index. Further adjustment for cardiovascular disease, diabetes (excluding treatment with 
insulin and/or hypoglycemic drugs in the model), physical at work (sitting [reference], light, moderate, 
and hard), and physical activity at leisure (sitting [reference], light, moderate, and hard) did not affect 
the difference in log-HOMA-IR across tertiles of ferritin (P=0.039 ANCOVA).   
